Ingredient

Black cohosh

Products with Black cohosh on sale in the United Kingdom.

Find products
Share

Email article

Published

Black cohosh is a plant, Actaea racemosa, also called Cimicifuga racemosa. It is a perennial of the buttercup family, native to North America. Supplements contain its root and rhizome, as powder, liquid extracts or dried extracts in pills. Extracts are often standardized to triterpene glycosides, compounds of the root.

Terms and sources
Actaea racemosa
NCCIH lists the common names black cohosh, black snakeroot, macrotys, bugbane, bugwort, rattleroot and rattleweed.
buttercup family
NIH Office of Dietary Supplements, black cohosh fact sheet for health professionals.
rhizome
An underground stem. NIH Office of Dietary Supplements.
triterpene glycosides
NIH notes that products are frequently standardized to at least 1 mg of triterpene glycosides per daily dose.

Black cohosh in the body

Black cohosh is not a nutrient, and the body has no daily requirement for it. Trials of its extracts in women around menopause measure hot flashes, night sweats and symptom scores.

NIH notes that available preparations vary considerably in chemical composition. NIH adds that the compounds behind any effect are not known. Compounds named as candidates include triterpene glycosides such as actein and 23-epi-26-deoxyactein. In one study, 15 women after menopause took single doses with 1.4, 2.8 or 5.6 mg of 23-epi-26-deoxyactein. Its half-life in blood was about 2 hours at all three doses. Less than 0.01% of the dose was recovered in urine within 24 hours.

Terms and sources
23-epi-26-deoxyactein
NIH also names resins, such as cimicifugin, and caffeic, isoferulic and fukinolic acids. NIH Office of Dietary Supplements.
15 women after menopause
A 75% ethanol extract. van Breemen et al., Clinical Pharmacology and Therapeutics, 2010.
half-life
The time for the blood level to fall by half. van Breemen et al., 2010.
Less than 0.01%
Of the 23-epi-26-deoxyactein taken. van Breemen et al., 2010.

NIH, health risks: "Clinical trials using various black cohosh preparations to treat menopausal symptoms have shown that its use is associated with a low incidence of adverse effects." NIH adds: "The most commonly reported side effects are gastrointestinal upset and rashes, both of which are mild and transient." NIH adds: "Other reported adverse effects in clinical trials have included breast pain/enlargement, infection, vaginal bleeding/spotting, and musculoskeletal complaints, although their incidence was similar in women taking black cohosh and those taking placebo." NIH adds: "Most studies have examined black cohosh use for short periods, typically 6 months or less, so no published studies have assessed the long-term safety of black cohosh in humans."

Terms and sources
health risks
The NIH section on health risks, quoted in full in this paragraph and the next three. Reference numbers are left out. NIH Office of Dietary Supplements.

NIH, on the liver: "Across the world, reports have described at least 83 cases of liver damage—including hepatitis, liver failure, elevated liver enzymes, and assorted other liver injuries—associated with black cohosh use." NIH adds: "However, there is no evidence of a causal relationship." NIH adds: "It is possible that at least some reported cases of hepatotoxicity were due to impurities, adulterants, or incorrect Acteae species in the black cohosh products used." NIH adds: "However, no one independently analyzed these products to confirm the existence of these problems."

Terms and sources
Acteae
Spelled this way in the NIH text; the genus is Actaea.

NIH, on labels: "In 2007, the Australian Department of Health began requiring that products containing black cohosh carry the following label statement: 'Warning: Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional'." NIH adds: "In 2008, the U.S. Pharmacopeia (a nonprofit standard-setting organization for foods and drugs) recommended labeling black cohosh products with the following cautionary statement: 'Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice'." NIH adds: "However, the U.S. Food and Drug Administration does not require such a warning on black cohosh product labels."

NIH adds: "The American Herbal Products Association recommends that pregnant women not take black cohosh except under the supervision of their health care provider because studies have not rigorously evaluated its use during pregnancy." NIH adds: "The U.S. Pharmacopeia advises that individuals with liver disorders should also avoid black cohosh." NIH adds: "It adds that users who develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice, while taking the supplement should discontinue use and contact their doctor." NIH, on medicines: "Black cohosh is not known to have any clinically relevant interactions with medications, although this has not been systematically studied."

Terms and sources
on medicines
The NIH section on interactions with medications, quoted in full. NIH Office of Dietary Supplements.

NCCIH, on safety: "While black cohosh has been used safely in research studies that lasted as long as a year and is generally well tolerated, concerns have been raised that it may cause liver damage in some people." NCCIH adds: "Cases of liver damage—some very serious—have been reported in people taking products labeled as black cohosh." NCCIH adds: "These problems are rare, and it’s uncertain whether black cohosh was responsible for them." NCCIH adds: "If you take black cohosh, consult your health care provider if you develop symptoms of liver damage such as dark urine and fatigue." NCCIH adds: "Some commercial black cohosh products have been found to contain the wrong herb or to contain mixtures of black cohosh and other herbs that are not listed on the label." NCCIH adds: "It is possible but not proven that these contaminants might be responsible for cases of liver damage linked to black cohosh products." NCCIH adds: "Black cohosh and blue cohosh (Caulophyllum thalictroides) are different herbs." NCCIH adds: "Blue cohosh may cause adverse effects such as high blood pressure, high blood sugar, and chest pain." NCCIH adds: "The use of blue cohosh to induce labor has been associated with life-threatening complications in the infant, including seizures." NCCIH adds: "It’s uncertain whether black cohosh is safe for women who have had hormone-sensitive conditions such as breast or uterine cancer." NCCIH adds: "If you take any type of medicine, talk with your health care provider before using black cohosh or other herbal products; some herbs and medicines interact in harmful ways." NCCIH adds: "Black cohosh may not be safe for use during pregnancy or while breastfeeding."

Terms and sources
on safety
The NCCIH safety section, quoted in full in this paragraph. NIH National Center for Complementary and Integrative Health (NCCIH), black cohosh page.

Where black cohosh comes from

Black cohosh grows in North America. Other, mostly historical, names include snakeroot, black bugbane, rattleweed and macrotys. Native Americans used it, and it has been used medicinally in Germany since the late 19th century.

Terms and sources
North America
NIH National Center for Complementary and Integrative Health (NCCIH), black cohosh page.
mostly historical
NIH lists one more name. NIH Office of Dietary Supplements.
since the late 19th century
NIH National Center for Complementary and Integrative Health (NCCIH), black cohosh page.

Herbal preparations use the root or rhizome. In one analysis of 11 black cohosh products, 3 held Asian Actaea species instead of black cohosh. One more product held both black cohosh and an Asian Actaea species. Black cohosh and blue cohosh are different plants.

Terms and sources
root or rhizome
NCCIH and the NIH Office of Dietary Supplements.
Asian Actaea
They held the marker compound cimifugin and lacked cimiracemoside C. Jiang et al., Journal of Agricultural and Food Chemistry, 2006.
One more product
Jiang et al., 2006. NIH cites this analysis in its section on health risks.
blue cohosh
Caulophyllum thalictroides. NCCIH.

Daily amounts and the upper limit

United States

There is no US recommended daily amount for black cohosh. The National Academies have not set an upper limit for black cohosh.

In the NIH label database, 1,449 US labels list black cohosh, and 82% of them list other ingredients too. Of these labels, 32 also list blue cohosh, a different plant. Another 50 labels name only another Cimicifuga species. On 3 labels, the name black cohosh stands next to Cimicifuga foetida.

Terms and sources
1,449 US labels
NIH Dietary Supplement Label Database, including products no longer sold. Labels with an ingredient or blend part named black cohosh or Actaea or Cimicifuga racemosa. We counted these.
82%
1,191 of 1,449. Labels where every ingredient is black cohosh or its compounds are counted as black cohosh only. Calorie and carbohydrate rows are ignored.
32 also list blue cohosh
Caulophyllum thalictroides. We counted these.
another Cimicifuga species
Cimicifuga heracleifolia, Cimicifuga foetida, or Chinese cimicifuga. These 50 labels are not in the 1,449. We counted these.
On 3 labels
Such as black cohosh (Cimicifuga foetida) root extract. One of them is among the 1,449, two among the 50.

In 134 extract labels whose only ingredient is black cohosh, the middle half list 40–250 mg per serving. Labels that do not call it an extract list more: the middle half of 93 list 200–540 mg.

Terms and sources
134 extract labels
The median is 100 mg. Amounts in mg or g, converted to mg. A serving is not always a full day's amount.
per serving
Left out: 11 labels in mL, 14 with no amount, and 6 that list black cohosh twice. We counted these.
93
Ingredient names without the word extract. 19 of them give triterpene glycosides as the form. The median is 540 mg.

Of the 1,449 labels, 362 mention triterpenes. Of 75 labels that give both the black cohosh amount and its triterpene amount in mg, 51 come to 2.5%. Six labels named Remifemin list 20 mg of RemiSure extract or 2.5 mg of RemiSure dry extract.

Terms and sources
362 mention triterpenes
In an ingredient name, a form or a separate row. We counted these.
51 come to 2.5%
By our calculation. 12 come to under 1%, 7 to 1%, and 5 to 2.22–2.48%.
75 labels
On these labels, the most common triterpene amount was 1 mg per serving. On 13 of them, the black cohosh row is not called an extract.
Six labels named Remifemin
Remifemin is the product name. Three list 20 mg of RemiSure black cohosh extract, two list 2.5 mg, and one gives no amount. Amounts are per serving. We counted these.

Of 258 labels whose only ingredient is black cohosh, 55 carry a precaution that mentions the liver.

Terms and sources
55 carry a precaution
A precaution statement on the label with the word liver. 36 of them carry a version of the US Pharmacopeia wording, with the words symptoms of liver trouble.
258 labels
Across all 1,449 labels: 243 and 173. We counted these.

Forms of black cohosh and how they differ

Extracts differ in solvent, in the ratio of herb to extract, and in what they are standardized to. NIH notes that Remifemin is extracted with isopropyl alcohol and is not standardized to triterpene glycoside content. A review by its maker's staff calls the Remifemin extract iCR. Ze 450 is a 60% ethanol extract of rhizome and root, 4.5 to 8.5 parts herb to 1 part extract. We do not rank extracts.

Terms and sources
Remifemin
NIH: equivalent to 40 mg of root and rhizome per daily dose of two tablets; reformulated over time. NIH Office of Dietary Supplements.
its maker's staff
The author works for Schaper & Brümmer, named in the review as the maker. Henneicke-von Zepelin, Wiener Medizinische Wochenschrift, 2017.
Ze 450
From Max Zeller Söhne AG, per the trial report. Schellenberg et al., Evidence-Based Complementary and Alternative Medicine, 2012.
Remifemin, Ze 450, BNO 1055 and other black cohosh extracts
FormWhat it isStudies below
Remifemin (iCR)Isopropyl alcohol extract, equivalent to 40 mg of root and rhizome per daily doseNot in the studies below.
Ze 45060% ethanol extract, 4.5–8.5 parts herb to 1 part extractMenopausal symptom scores: Schellenberg 2012.
BNO 1055Extract sold as Klimadynon or Menofem; dose stated as 40 mg of herbal drugMenopausal symptom scores: Wuttke 2003.
Cr 99Dried ethanol extract of the rootHot flash scores: Frei-Kleiner 2005.
Cimifugol6.5 mg of dried root extract, 0.12–0.18 mg of 27-deoxyactein per tabletMenopausal symptom scores: Mohammad-Alizadeh-Charandabi 2013.
Ethanol extract with stated triterpene glycosides160 mg with 2.5%, or 128 mg with 7.27 mg a dayHot flashes, blood tests, thinking tests: Newton 2006, Spangler 2007, Reed 2008, Geller 2009, Maki 2009.
Root powderPowdered whole herb from root and rhizomeNot tested as a named form in the studies below.
Asian Actaea speciesDifferent species, found in place of black cohosh in some productsNot in the studies below.

What it is: NIH Office of Dietary Supplements and Henneicke-von Zepelin 2017 (Remifemin). Schellenberg 2012 (Ze 450); Wuttke 2003 (BNO 1055). Also: Frei-Kleiner 2005 (Cr 99); Mohammad-Alizadeh-Charandabi 2013 (Cimifugol). NIH and Geller 2009 (ethanol extracts); NIH (root powder); Jiang 2006 (Asian Actaea).

Published studies of black cohosh

NIH describes a 2012 review of 16 trials in 2,027 women around menopause. NIH notes that the review's authors found insufficient evidence for or against black cohosh for menopausal symptoms. NCCIH: "A substantial number of studies in people have evaluated black cohosh for menopause symptoms."

Terms and sources
a 2012 review
Leach and Moore, Cochrane review. Some of its trials enrolled women with a diagnosis. NIH Office of Dietary Supplements.
NCCIH
NIH National Center for Complementary and Integrative Health (NCCIH), black cohosh page, section How Much Do We Know?

Trials in women with a diagnosis, trials of mixtures and trials of other Cimicifuga species are not listed here.

10 reports from 7 trials in women around menopause: 2 found a difference, 6 none, 2 mixed.

Three reports come from one trial of 351 women, and two from one trial of 89 women. None of them selected women by a diagnosis. Not listed: trials in women with a diagnosis, or selected by a sleep complaint. Also not listed: mixtures, other Cimicifuga species, and trials without a dummy group. Also not listed: medicine-interaction studies and a study without stated random allocation. Also not listed: a trial with an unread correction, and a review whose trial list we could not read. Also not listed: reviews that include mixtures or women with a diagnosis, and second reports of two listed trials. Also not listed: a report whose comparison with the dummy group we could not confirm.

Our one-line summary comes first. The original is on PubMed.

Show the 10 studies
  • For a year, women around menopause took black cohosh or a dummy capsule; hot flashes did not differ.

    Trial · in all five groups · 1 year · funding not stated

    Newton et al., Annals of Internal Medicine, 2006

    Terms and sources
    women around menopause
    351 women aged 45 to 55, with 2 or more hot flashes or night sweats a day. 52% were in the menopausal transition.
    black cohosh
    160 mg a day. NIH describes it as a 70% ethanol extract with 2.5% triterpene glycosides. Other groups took herbal mixtures or a hormone medicine.
    hot flashes did not differ
    Hot flashes and night sweats per day, their intensity, and a hot-flash scale, at 3, 6 and 12 months. The average difference from the dummy capsule was under 1 a day. Letters on this trial were published, with a reply. We could not read them. An editorial and other comments on this trial were also published; we could not read them.
    a dummy capsule
    The trial was double-blind.
    funding not stated
    PubMed's record notes NIH extramural research funding. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    A trial in Washington State compared black cohosh, two herbal mixtures, a hormone medicine and a dummy capsule. 351 women aged 45 to 55 took them for a year. The black cohosh group took 160 mg a day. Hot flashes and night sweats per day did not differ from the dummy capsule at 3, 6 or 12 months. Their intensity did not differ either. With the hormone medicine, there were about 4 fewer a day than with the dummy capsule. Funding: we could not read the funding section.

  • Women around menopause: after 3 months, blood fats, sugar and insulin did not differ between black cohosh and dummy capsules.

    Trial · in all five groups; 310 had blood measures · 3 months · funding not stated

    Spangler et al., Maturitas, 2007

    Same participants as Newton 2006

    Terms and sources
    blood fats, sugar and insulin
    Total, LDL and HDL cholesterol, triglycerides, glucose, insulin and fibrinogen, measured in 310 women.
    black cohosh
    160 mg a day, in the same trial as Newton 2006.
    funding not stated
    PubMed's record notes NIH extramural research funding. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    This report of the same 351-woman trial looked at blood tests after 3 months. 310 women had them measured. Cholesterol, triglycerides, glucose and insulin changed no differently with black cohosh than with the dummy capsule. Fibrinogen appeared to rise with one herbal mixture. Its difference from the dummy capsule was not statistically significant. Funding: we could not read the funding section.

  • After a year, hormone levels and vaginal cell tests did not differ between black cohosh and dummy capsules.

    Trial · in all five groups · 1 year · funding not stated

    Reed et al., Menopause, 2008

    Same participants as Newton 2006

    Terms and sources
    hormone levels
    Estradiol, FSH, LH and SHBG, at the start and at 12 months, in 133 women after menopause.
    vaginal cell tests
    Vaginal cells and dryness at 3 and 12 months. Bleeding diaries in 313 women showed no difference either. An editorial on this report was also published; we could not read it. A letter on this report was published, with a reply. We could not read them.
    black cohosh
    160 mg a day, in the same trial as Newton 2006.
    funding not stated
    PubMed's record notes NIH extramural research funding. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    This report of the same trial looked at hormone levels and gynecological tests over a year. Vaginal cells, dryness and bleeding did not differ between black cohosh and the dummy capsule. In 133 women after menopause, estradiol, FSH and LH did not differ either. The hormone medicine group differed on these measures. Funding: we could not read the funding section.

  • In women with menopausal symptoms, scores fell more with Ze 450 than with a dummy tablet over 12 weeks.

    Trial · 180 people · 12 weeks · maker-funded

    Schellenberg et al., Evidence-Based Complementary and Alternative Medicine, 2012

    Terms and sources
    women with menopausal symptoms
    180 women aged 40 or over, from 4 clinics. A doctor confirmed menopausal complaints with a symptom score. About 23% had not reached menopause.
    Ze 450
    A 60% ethanol extract of rhizome and root, 6.5 mg or 13 mg a day. It came from Max Zeller Söhne AG, per the methods. Possibly related side effects: 5 with the dummy tablet, 2 with each dose.
    scores fell more
    Kupperman Index, a menopausal symptom score. Both doses differed from the dummy tablet; the difference was statistically significant and larger with 13 mg.
    a dummy tablet
    Identical-looking tablets; each group took two a day.
    maker-funded
    Funded by Max Zeller Söhne AG, named in the methods as the source of Ze 450. Three authors work for the company.

    Study · Free full text · about 18 min to read

    Our estimate at about 200 words a minute, from the PMC full text without tables.

    Study summary

    Women with menopausal complaints took 13 mg of Ze 450, 6.5 mg, or a dummy tablet for 12 weeks. 180 women aged 40 or over took part. Kupperman Index scores fell more with both doses than with the dummy tablet. The difference was larger with 13 mg. The score fell by half or more in 69% with 13 mg and 40% with 6.5 mg. With the dummy tablet, it did so in 7%. Side effects were few in all groups. Funding: Max Zeller Söhne AG, whose staff include three authors.

  • Women with daily hot flashes took Cr 99 or a dummy product for 12 weeks; scores did not differ.

    Trial · randomized, per the Cochrane review; 122 in the intention-to-treat analysis · 12 weeks · funding not stated

    Frei-Kleiner et al., Maturitas, 2005

    Terms and sources
    daily hot flashes
    3 or more hot flashes a day. 14 centers in Switzerland, per the Cochrane review.
    Cr 99
    A black cohosh root extract, as the abstract names it. 6.5 mg of dry extract a day, per the Cochrane review. The abstract does not name the maker. Side effects did not differ between the groups.
    scores did not differ
    Weekly hot-flash score and Kupperman Index, the two main measures. With a starting Kupperman Index of 20 or more, the Kupperman Index and Menopause Rating Scale differed. In that subgroup, the hot-flash score just missed statistical significance.
    a dummy product
    Capsules with excipients only, per the Cochrane review.
    funding not stated
    We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    129 women with 3 or more hot flashes a day were randomized. 122 were in the main analysis. They took the Cr 99 extract or a dummy product for 12 weeks. The two main measures did not differ between groups overall. With a starting Kupperman Index of 20 or more, the Kupperman Index and Menopause Rating Scale differed. The hot-flash score just missed statistical significance. Side effects did not differ. Funding: we could not read the funding section.

  • Over a year, hot flash counts did not differ from a dummy capsule; intensity was higher with black cohosh.

    Trial · in all four groups · 12 months · maker-funded

    Geller et al., Menopause, 2009

    Terms and sources
    hot flash counts
    Hot flashes and night sweats per week, in 89 women with at least 35 a week. They fell 34% with black cohosh and 63% with the dummy capsule.
    intensity was higher
    Statistically significant at 6 and 9 months. At 3 months, Kupperman and Greene vasomotor scores were also higher with black cohosh.
    black cohosh
    128 mg a day of an ethanol extract of the underground parts, with 7.27 mg of triterpene glycosides. Other groups took red clover or a hormone medicine. Liver tests and the other safety measures did not differ from the dummy capsule.
    a dummy capsule
    Rice powder in the same olive green capsule as the other groups.
    maker-funded
    Funded by NIH, with backing from Pharmavite to the University of Illinois Foundation. Pharmavite made the capsules and Pureworld the extract. One author was a paid consultant to Pharmavite.

    Study · Free full text · about 21 min to read

    Our estimate at about 200 words a minute, from the PMC full text without tables.

    Study summary

    89 women had at least 35 hot flashes or night sweats a week. For a year, they took black cohosh, red clover, a hormone medicine or a dummy capsule. Counts fell 34% with black cohosh and 63% with the dummy capsule. The difference was not statistically significant. Intensity was higher with black cohosh at 6 and 9 months. Liver tests did not differ between groups. Funding: NIH, with backing from Pharmavite to the University of Illinois Foundation. Pharmavite made the capsules and Pureworld the extract. One author was a paid consultant to Pharmavite.

  • After a year, memory and other thinking tests did not differ between black cohosh and a dummy capsule.

    Trial · of 89 in the parent trial, all four groups · 12 months

    Maki et al., Menopause, 2009

    Same participants as Geller 2009

    Terms and sources
    memory and other thinking tests
    Word-list and story recall, attention, verbal fluency, figure memory and spatial tests, before and in the 12th month. 26% of the parent trial's women were not in this analysis; the authors list this as a possible bias.
    black cohosh
    128 mg a day, the same extract and women as in Geller 2009. Funded by NIH grants.

    Study · Free full text · about 28 min to read

    Our estimate at about 200 words a minute, from the PMC full text without tables.

    Study summary

    66 women from the Geller 2009 trial did memory and thinking tests before and after a year. Groups took black cohosh, red clover, a hormone medicine or a dummy capsule. No memory or other thinking test changed differently with black cohosh than with the dummy capsule. The hormone medicine group scored lower on one word-list measure. Funding: NIH grants.

  • Women after menopause took Cimifugol or a dummy tablet for 8 weeks; symptom scores fell more with Cimifugol.

    Trial · 84 people · 8 weeks

    Mohammad-Alizadeh-Charandabi et al., Chinese Medicine, 2013

    Terms and sources
    Women after menopause
    84 women aged 45 to 60 in Tehran, with Greene Climacteric Scale scores of 15 to 42.
    Cimifugol
    Tablets with 6.5 mg of dried root extract, bought at a pharmacy. Each held 0.12–0.18 mg of 27-deoxyactein. Funded by Tabriz University of Medical Sciences. The authors declare no competing interests.
    symptom scores fell more
    Total score and all four parts, including hot flashes, at 4 and 8 weeks. All differences were statistically significant. No side effects were reported in either group.

    Study · Free full text · about 14 min to read

    Our estimate at about 200 words a minute, from the PMC full text without tables.

    Study summary

    84 women after menopause in Tehran took part. Each night for 8 weeks, they took a 6.5 mg Cimifugol tablet or a dummy tablet. Greene Climacteric Scale scores fell more with Cimifugol at 4 and 8 weeks. All four parts of the scale differed, including hot flashes. No side effects were reported, and no one left the trial. Funding: Tabriz University of Medical Sciences. The authors declare no competing interests.

  • Women after menopause took BNO 1055 or a dummy product; symptom scores differed only in the 62 analyzed per protocol.

    Trial · randomized; 62 analyzed, per the paper · 3 months · industry author

    Wuttke et al., Maturitas, 2003

    Terms and sources
    Women after menopause
    97 women were randomized, for 3 months. A third group took a hormone medicine.
    BNO 1055
    Sold as Klimadynon or Menofem, the paper says. A 58% ethanol extract of the rhizome; the daily dose corresponds to 40 mg of herbal drug.
    symptom scores differed
    Menopause Rating Scale, the main measure. In the 62, scores fell more with BNO 1055 than with the dummy product. The hot flash items alone did not differ significantly. Superficial vaginal cells rose slightly with BNO 1055 and fell with the dummy product. The difference was not statistically significant.
    per protocol
    2 left early, and 33 were excluded for hormone levels or weight outside the criteria. The paper says the analysis of all 97 randomized showed no significant differences between groups.
    industry author
    1 of 3 authors worked for Bionorica AG. Grants from an EU program and the German Research Society paid for part of the work. The paper mentions a sponsor but does not name it.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    97 women after menopause were randomized to BNO 1055, a hormone medicine or a dummy product for 3 months. 2 left early, and 33 were excluded for hormone levels or weight outside the criteria. In the 62 analyzed, Menopause Rating Scale scores fell more with BNO 1055 than with the dummy product. The paper says the analysis of all 97 showed no significant differences between groups. Endometrial thickness did not change with BNO 1055. Superficial vaginal cells rose slightly with BNO 1055 and fell with the dummy product. That difference was not statistically significant. Funding: in part an EU program and the German Research Society. One author worked for Bionorica AG.

  • Thai women with menopausal symptoms took a black cohosh extract or a dummy product; symptom scores did not differ.

    Trial · 54 people · funding not stated

    Tanmahasamut et al., Climacteric, 2015

    Terms and sources
    Thai women with menopausal symptoms
    54 women aged 40 or over, at a university hospital menopause clinic, with moderate to severe Kupperman scores.
    a black cohosh extract
    40 mg a day. The abstract does not name the brand or state how long the trial lasted.
    symptom scores did not differ
    Kupperman Index, hot flashes per day, quality of life and satisfaction. Liver tests did not change significantly.
    funding not stated
    PubMed's record notes research funding from outside the US government. We could not read the funding section of this paper.

    Study · Abstract only · about 2 min to read

    Abstract only; about 2 minutes.

    Study summary

    54 Thai women aged 40 or over had moderate to severe menopausal symptoms. They took 40 mg of black cohosh extract a day or a dummy product. Symptom scores and hot flashes fell over time in both groups. The differences between groups were not statistically significant. Liver tests did not change significantly. Funding: we could not read the funding section.

Sources

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.

Products with Black cohosh on sale in the United Kingdom

View products with filters

Lowest price per day first. Status shown for the United Kingdom.

No products match this list.

Not sure what to choose, or couldn’t find what you were looking for? Ask our expert

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own. If you have a health condition, are pregnant or breastfeeding, take medicines, or are under 18, talk to a doctor or pharmacist first.